Roche Pharmaceutical Development and Sales Overview
Tiragolumab (anti-TIGIT, RG6058, MTIG7192A)
Monoclonal antibody targeting the immune checkpoint inhibitor TIGIT
Indication
1L NSCLC PD-L1 TPS>50%
Stage III unresectable 1L NSCLC
Phase/study
Phase III
SKYSCRAPER-01
# of patients
N=500-560
ARM A: Tiragolumab plus Tecentriq
ARM B: Placebo plus Tecentriq
Design
Phase III
SKYSCRAPER-03
N=800
ARM A: Tiragolumab plus Tecentriq for up to 12 months
ARM B: Durvalumab for up to 12 months
Overall survival and progression-free survival
ā
Progression-free survival
Primary endpoint
FPI Q1 2020
FPI Q3 2020
Status
Recruitment completed Q3 2021
Study did not meet one of its primary endpoints, PFS Q2 2022
CT Identifier
NCT04294810
NCT04513925
NSCLC=Non-small cell lung cancer; ES-SCLC-Extensive stage small cell lung cancer; PD-L1-Programmed cell death-ligand 1; TPS-Tumor Proportion Score; PFS-Progression-free survival
105
Roche
OncologyView entire presentation